Tajammul Fazili

Louisiana State University Health Sciences Center Shreveport

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Yunshin Yeh

Overton Brooks VA Medical Center

A. Lurie

University of California, Berkeley

Xiuping Yu

Louisiana State University Health Sciences Center Shreveport

Michael Constantinescu

Louisiana State University

Shu Yang

Louisiana State University Health Sciences Center Shreveport

Anthony Tanner

Overton Brooks VA Medical Center

Chryssanthos Kouriefs

Limassol General Hospital

Catherine Chaudoir

Overton Brooks VA Medical Center

S. Masood

Dr. Ram Manohar Lohia Institute of Medical Sciences

G.R. Mufti

Medway Maritime Hospital

Cooperative Institutions

Louisiana State University Health Sciences Center Shreveport

University of South Florida

Moffitt Cancer Center

Overton Brooks VA Medical Center

Louisiana State University

Louisiana State University in Shreveport

Florida College

Medway Maritime Hospital

Louisiana State University Health Sciences Center New Orleans

University of Florida

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer

Contemporary Clinical Trials (2011)

Nagi B. Kumar Theresa Crocker Tiffany Smith Julio M. Pow‐Sang Philippe E. Spiess

Outreach

Patient recruitment

10.1016/j.cct.2011.11.004

Cite

Citations (17)

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

Prostate Cancer and Prostatic Diseases (2020)

Siyuan Cheng Néstor Prieto‐Domínguez Shu Yang Zachary M. Connelly Samantha StPierre

YAP1

Neuroendocrine differentiation

10.1038/s41391-020-0229-z

Cite

Citations (36)

Incidentally Detected Prostate Cancer in Cystoprostatectomy Specimens

Urologia Internationalis (2005)

Chryssanthos Kouriefs Tajammul Fazili S. Masood Madiha Naseem G.R. Mufti

Objectives: Bladder and prostate cancers occur with increasing prevalence in the ageing population. Our study aims to quantify the incidence of prostate cancer in patients undergoing cystoprostatectomy for bladder cancer and assess the impact of that incidental prostate cancer on oncological outcome. Methods and Materials: We retrospectively reviewed the pathology reports of 128 men who underwent cystoprostatectomy for bladder cancer. Results: Twenty-three men (18%) were found to have incidental prostate cancer. All incidental prostate cancers were organ confined and 91% were well or moderately differentiated. At a mean follow-up of 55 months the prostate cancer-free survival was 96%. Conclusion: The incidence of prostate cancer in cystoprostatectomy specimens is high. When the prostate is removed completely the presence of incidental prostate cancer does not influence the overall oncological outcome.

Cystoprostatectomy

10.1159/000087796

Cite

Citations (31)

Nephrogenic Adenoma of the Prostatic Urethra Mimicking Prostatic and Bladder Carcinomas

Cureus (2023)

Maria Carolina Beeter Tajammul Fazili Yunshin Yeh

A nephrogenic adenoma is a benign lesion consisting of the proliferation of tubules and glands in the urinary tract. The lesion, thought to be originated from renal tubules, is commonly seen in the urinary bladder. Microscopically, nephrogenic adenoma is composed of a proliferation of small tubules and microcysts encircled by a narrow rim of basement membrane-like hyaline material. There are tubules and microcysts lined by atrophic to undulating hobnail-appearing epithelial cells with bland nuclei and pale eosinophilic to clear cytoplasm. Focal cellular atypia characterized by somewhat coarse chromatin and prominent nucleoli may be present. The stroma is edematous and reveals a granulation tissue-like appearance. By immunohistochemical staining, nephrogenic adenoma is positive for PAX-2, PAX-8, P504S (α-methylacyl-CoA racemase), pan cytokeratin AE1/AE3, CK7, CAM5.2, epithelial membrane antigen (EMA), CD10, and napsin A. Occasionally the lesions are incidentally encountered in the prostatic urethra, which may lead to a misdiagnosis as prostatic adenocarcinoma, clear cell adenocarcinoma or urothelial carcinoma of the urinary bladder. Herein we present a case of nephrogenic adenoma which has been incidentally found in a transurethral resection of a prostate specimen for the management of benign prostatic hypertrophy. The evaluation of morphology, immunohistochemistry, and differential diagnoses have also been discussed.

Atypia

Prostatic urethra

10.7759/cureus.35998

Cite

Citations (2)

Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures

Journal of Clinical Trials (2012)

Nagi B. Kumar Theresa Crocker Tiffany Smith Shahnjayla K. Connors Julio M. Pow‐Sang

In spite of the large number of nutrient-derived agents demonstrating promise as potential chemopreventive agents, most have failed to prove effectiveness in clinical trials. Critical requirements for moving nutrient-derived agents to recommendation for clinical use include adopting a systematic, molecular-mechanism based approach and utilizing the same ethical and rigorous methods such as are used to evaluate other pharmacological agents. Preliminary data on a mechanistic rationale for chemoprevention activity as observed from epidemiological, in vitro and preclinical studies, phase I data of safety in suitable cohorts, duration of intervention based on time to progression of preneoplastic disease to cancer and the use of a valid panel of biomarkers representing the hypothesized carcinogenesis pathway for measuring efficacy must inform the design of phase II clinical trials. The goal of this paper is to provide a model for evaluating a well characterized agent- Polyphenon E- in a phase II clinical trial of prostate cancer chemoprevention.

Clinical study design

10.4172/jctr.1000105

Cite

Citations (9)

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

bioRxiv (Cold Spring Harbor Laboratory) (2019)

Siyuan Cheng Néstor Prieto‐Domínguez Shu Yang Zachary M. Connelly Samantha StPierre

ABSTRACT BACKGROUND After long-term androgen deprivation therapy, 25-30% prostate cancer (PCa) acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a key transcription coactivator of the Hippo pathway, has been related to cancer progression. However, its role in neuroendocrine prostate cancer (NEPC) has not been assessed. METHODS Immunohistochemistry was used to evaluate YAP1 protein levels during PCa initiation and progression. YAP1 knockdown and luciferase reporter assays were used to evaluate the ability of YAP1 to modulate Wnt/beta-Catenin signaling. RESULTS YAP1 expression was present in the basal epithelial cells in benign prostatic tissues, lost in low grade PCa, but elevated in high grade prostate adenocarcinomas. Interestingly, the expression of YAP1 was reduced/lost in both human and mouse NEPC. Finally, YAP1 knockdown in PCa cells activates Wnt/beta-Catenin signaling, which has been implicated in NE differentiation of PCa, supporting a functional involvement of the loss of YAP1 expression in NEPC development. CONCLUSIONS The expression of YAP1 is elevated in high grade prostate adenocarcinomas while lost in NEPC. Reduced YAP1 activates Wnt/beta-Catenin signaling in PCa cells. These results suggest that when applied to PCa patients, YAP1 inhibitors shall be used with caution.

YAP1

Hippo signaling pathway

10.1101/832360

Cite

Citations (8)

Large-Cell Neuroendocrine Carcinoma of the Prostate

AJSP Review and Reports (2021)

Yunshin Yeh Michael Constantinescu Catherine Chaudoir Anthony Tanner Shu Yang

Primary large-cell neuroendocrine carcinoma of the prostate is very rare. The tumor genomic alterations have not been reported. We report a case of a 78-year-old man with a recurrent large-cell prostatic neuroendocrine carcinoma with distinctive pathological features and genetic changes including ATM frameshift duplication, TP53 missense mutation, and a chromosomal translocation leading to STAG2-BTD gene fusion.

10.1097/pcr.0000000000000441

Cite

Citations (0)

1037: Radical Retropubic Prostatectomy After Transurethral Resection of Prostate & Hellip; Does it Influence the Overall Outcome?

The Journal of Urology (2004)

Muhammad S. Naseem Seshadri Sriprasad Chryssanthos Kouriefs Tajammul Fazili Shikohe Masood

You have accessJournal of UrologyDiscussed Poster, Monday, May 10, 2004, 1:00 - 5:00 pm1 Apr 20041037: Radical Retropubic Prostatectomy After Transurethral Resection of Prostate & Hellip; Does it Influence the Overall Outcome? Muhammad S. Naseem, S. Sriprasad, Chryssanthos Kouriefs, Tajammul Fazili, Shikohe Masood, and Guizar Mufti Muhammad S. NaseemMuhammad S. Naseem More articles by this author , S. SriprasadS. Sriprasad More articles by this author , Chryssanthos KouriefsChryssanthos Kouriefs More articles by this author , Tajammul FaziliTajammul Fazili More articles by this author , Shikohe MasoodShikohe Masood More articles by this author , and Guizar MuftiGuizar Mufti More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(18)38274-0AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "1037: Radical Retropubic Prostatectomy After Transurethral Resection of Prostate & Hellip; Does it Influence the Overall Outcome?." The Journal of Urology, 171(4S), p. 274 © 2016 by American Urological AssociationFiguresReferencesRelatedDetails Volume 171Issue 4SApril 2004Page: 274 Advertisement Copyright & Permissions© 2016 by American Urological AssociationMetricsAuthor Information Muhammad S. Naseem More articles by this author S. Sriprasad More articles by this author Chryssanthos Kouriefs More articles by this author Tajammul Fazili More articles by this author Shikohe Masood More articles by this author Guizar Mufti More articles by this author Expand All Advertisement PDF downloadLoading ...

Radical retropubic prostatectomy

10.1016/s0022-5347(18)38274-0

Cite

Citations (0)

707Does pathological stage to in a cystectomy specimen imply freedom from bladder cancer?

European Urology Supplements (2005)

S. Masood Chryssanthos Kouriefs Tajammul Fazili Kaitlyn James D. Dawam

10.1016/s1569-9056(05)80711-0

Cite

Citations (0)

Fate of the Leftover Bladder After Supravesical Urinary Diversion for Benign Disease

The Journal of Urology (2006)

Tajammul Fazili Tahir Bhat Shikohe Masood John H. Palmer G.R. Mufti

We studied the fate of the leftover bladder in patients who underwent supravesical urinary diversion without cystectomy for benign pathology.This retrospective study was performed in 9 males and 15 females with a median age of 59 years in whom supravesical urinary diversion was performed for various benign conditions from 1996 to 2004. These conditions were incontinence, acontractile bladder, radiation and/or hemorrhagic cystitis, and neuropathic bladder. Median followup was 48 months.Of the patients 13 (54%) experienced problems with the retained bladder, 2 (8%) presented with urethral bleeding, which resolved by conservative means, and 11 (46%) had infective complications, which resolved with expectant treatment in 3 (12%). However, 8 patients (33%) had frank pyocystis and 3 (12%) were treated with the Spence procedure, which alleviated symptoms in only 1. Six patients (25%) required cystectomy.In patients undergoing supravesical urinary diversion for benign disease in whom the bladder remains in situ the risks of complications related to the defunctionalized bladder are more than 50% and 25% of patients subsequently need cystectomy. These patients should be offered primary cystectomy at urinary diversion.

Urinary diversion

10.1016/j.juro.2006.03.056

Cite

Citations (49)